DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT02671864

ANGIOSAFE2

UnknownPhase NA

Incretin-mimetic Hypoglycemic Drugs and Severe Retinopathy

Impact of Incretin-mimetic Hypoglycaemic Drugs on Diabetic Retinopathy in Type 2 Diabetic Patients and Study of Biomarkers in the Development of Severe Retinopathy: Angiosafe-T2D Study 2

Asset

GLP-1 / incretin class catch-all

Listed sites

2

Recruiting sites

—

Enrollment

7,200

estimated

Study population

Type 2 diabetes

Key I/E criterion

—

Primary endpoint

•Prevalence of Severe DR at V1 (inclusion)

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT02671864
Org study IDP150601

Timeline

Milestones

Study first posted2016-02-02estimated
Study start2016-04-11actual
Primary completion2022-04-11actual
Last update posted2023-03-06actual
Study completion2025-04-11estimated

Assets

Investigational agents

GLP-1 / incretin class catch-all

Study populations

Who this study enrolls

Type 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•T2D patients according to ADA criteria treated with any kind of hypoglycaemic treatment
•Age above 18 years

Exclusion criteria

•Type 1 diabetes
•Patients with cataract preventing DR grading
•Patients who had panretinal photocoagulation more than 10 years ago
•Documented pregnancy or lactation

Endpoints (6)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other (unclassified)
3
Other clinical outcomes
2
Cardiometabolic biomarkers
1

Cardiometabolic biomarkers

1 endpoint
Secondary/protocol endpoint

Plasma concentrations of ANGPT4

Time frame:at inclusion and 3 years

concentration, descriptive

Other clinical outcomes

2 endpoints
Primary/protocol endpoint

Prevalence of Severe DR at V1 (inclusion)

Time frame:at inclusion

categorical status, descriptive

Secondary/protocol endpoint

Prevalence of severe DR at V2 (after 3 years of treatment)

Time frame:after 3 years

categorical status, improvement

Other (unclassified)

3 endpoints
Secondary/protocol endpoint

Plasma concentrations of VEGF

Time frame:at inclusion and 3 years

concentration, descriptive

Secondary/protocol endpoint/low confidence

Plasma concentrations of proinflammatory cytokines such as IL-1beta, IL-6, IL-8, TNF-alpha

Time frame:at inclusion and 3 years

concentration, descriptive

Secondary/protocol endpoint/low confidence

Concentrations of blood circulating EPCs and PBMCs

Time frame:at inclusion and 3 years

descriptive

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.